Clinical Trials Sponsored by Precision Therapeutics

Total 6500 results

Lyra Therapeutics

Recruiting

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)

Chronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)

United States, Poland, Bulgaria, Belgium, Germany, Hungary
United Therapeutics

Recruiting

Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

Taiwan, Belgium, Spain, Korea, Republic of, Germany, Australia, Chile, Denmark, France, Mexico, Israel, Italy, Netherlands, Argentina, New Zealand, Peru
Stemirna Therapeutics

Recruiting

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Solid Tumor

Australia, Austria
iTeos Therapeutics

Recruiting

New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer

Solid Tumor, Adult

Belgium, United Kingdom
Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Alterity Therapeutics

Recruiting

Study of ATH434 in Participants With Multiple System Atrophy

Multiple System Atrophy

United States, Australia, New Zealand, United Kingdom, Italy, France, Austria
Protara Therapeutics

Recruiting

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (ADVANCED-1)

Non-muscle Invasive Bladder Cancer

United States, Moldova, Republic of, Romania, Ukraine
MapLight Therapeutics

Recruiting

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

United States, Australia, Canada
Plus Therapeutics

Recruiting

Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases (ReSPECT-LM)

Leptomeningeal Metastasis

United States
Aspa Therapeutics

Recruiting

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire)

Canavan Disease

United States
General Therapeutics

Not yet recruiting

Cell-free Stem Cell-derived Extract Formulation for Knee Osteoarthritis

Osteoarthritis, Knee
Aprea Therapeutics

Recruiting

Study Of ATRN-119 In Patients With Advanced Solid Tumors (ABOYA-119)

Advanced Solid Tumor

United States
ProQR Therapeutics

Recruiting

An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. (BRIGHTEN)

Eye Diseases | Neurologic Manifestations | Retinal Degeneration | Retinal Dystrophies | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

Belgium, Brazil, Canada, Germany, Italy, Netherlands, United Kingdom
Kamau Therapeutics

Recruiting

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease (RESTORE)

Sickle Cell Disease

United States
Cartesian Therapeutics

Recruiting

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Myeloma Multiple

United States
Amicus Therapeutics

Recruiting

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA)

Glycogen Storage Disease Type II Infantile Onset

United States, Taiwan, France, Germany, Italy, United Kingdom
AKARI Therapeutics

Recruiting

Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

Thrombotic Microangiopathies

United States, United Kingdom, Poland
Catapult Therapeutics

Recruiting

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic | SLL

United States, Spain
MitoImmune Therapeutics

Recruiting

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (MIT-001)

Head and Neck Squamous Cell Carcinoma | Oral Mucositis

Korea, Republic of, United States
Aligos Therapeutics

Recruiting

A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Chronic Hepatitis B

Hong Kong, China, United Kingdom, Moldova, Republic of, New Zealand, Australia, Mauritius
Lykos Therapeutics

Not yet recruiting

A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders (MED1)

Binge-Eating Disorder | Anorexia Nervosa Restricting Type
ImCheck Therapeutics

Recruiting

First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION)

Hematopoietic/Lymphoid Cancer | Solid Tumor, Adult

France, Belgium, United States, Germany, Spain, United Kingdom
Cartesian Therapeutics

Recruiting

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Myasthenia Gravis, Generalized

United States, Canada
Dragonfly Therapeutics

Recruiting

Study of DF1001 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States, Denmark, Netherlands, Belgium, France
Tarveda Therapeutics

Recruiting

PEN-866 in Patients With Advanced Solid Malignancies

Neoplasms | Carcinoma | Small Cell Lung Carcinoma | Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor | Gastric Adenocarcinoma | Small-cell Lung Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma | Adenocarcinoma of the Pancreas | Endometrial Adenocarcinoma | Squamous Cell Carcinoma of the Penis | Gastroesophageal... and other conditions

United States
Karuna Therapeutics

Enrolling by invitation

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia

United States, Bulgaria, Serbia, India, Poland, Romania, United Kingdom
Aerovate Therapeutics

Active, not recruiting

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) (IMPAHCT-FUL)

Pulmonary Arterial Hypertension

United States, Belgium, Spain, Australia, Canada, Singapore, China, Germany, Latvia, Italy, United Kingdom, Portugal, France, Mexico, Argentina, Poland, Chile, Israel, South Africa, Colombia
Karuna Therapeutics

Active, not recruiting

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

Schizophrenia

United States, Puerto Rico
Karuna Therapeutics

Enrolling by invitation

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease

Spain, United States, Belgium, Bulgaria, Canada, Chile, China, Croatia, Czechia, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Mexico, Peru, Poland, Serbia, Slovakia, Turkey, United Kingdom
United Therapeutics

Enrolling by invitation

Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-OLE)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

United States, Spain, Belgium, Australia, Taiwan, Israel, Korea, Republic of, Italy, France, Argentina, Chile, Denmark, Mexico, Netherlands
United Therapeutics

Terminated

Open-Label Study of Oral Treprostinil in Digital Ulcers (DISTOL-EXT)

Systemic Sclerosis

United States, Canada, United Kingdom
Cartesian Therapeutics

Active, not recruiting

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Relapse Multiple Myeloma

United States, Turkey
PTC Therapeutics

Enrolling by invitation

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

Inherited Mitochondrial Disease

United States, France, Spain, United Kingdom, Italy, Poland, Japan
Harpoon Therapeutics

Completed

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

Advanced Cancers Associated With Mesothelin Expression

United States
Sangamo Therapeutics

Enrolling by invitation

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

Blood and Lymphatic Diseases

United States
Aligos Therapeutics

Active, not recruiting

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) (HERALD)

Nonalcoholic Steatohepatitis | NASH | MASH | Metabolic Dysfunction-Associated Steatohepatitis

United States
Alaunos Therapeutics

Active, not recruiting

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Adenocarcinoma of Lung | Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Ovary Neoplasm | Adenosquamous Cell Lung Cancer

United States
Alaunos Therapeutics

Active, not recruiting

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Adenocarcinoma of Lung | Endometrial Cancer | Non-small Cell Lung Cancer | Ovarian Carcinoma | Squamous Cell Lung Cancer | Ovary Neoplasm | Adenosquamous Cell Lung Cancer

United States
United Therapeutics

Enrolling by invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Cardiovascular Diseases | Vascular Diseases | Lung Diseases | Hypertension | Connective Tissue Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Pulmonary Hypertension | PAH | Respiratory Tract Disease

United States, Spain, Australia, Taiwan, Canada, Singapore, United Kingdom, Italy, Germany, China, Mexico, Argentina, Korea, Republic of, Austria, Greece, Sweden, Portugal, Belgium, Brazil, Bulgaria, Chile, Croatia, Czechia, Denmark, Fr... and more
Beacon Therapeutics

Active, not recruiting

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (HORIZON)

X-Linked Retinitis Pigmentosa

United States
Monopar Therapeutics

Terminated

Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

Advanced Soft-tissue Sarcoma

United States
PTC Therapeutics

Active, not recruiting

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS (CARDINALS)

Amyotrophic Lateral Sclerosis

United States, Belgium, Spain, Australia, Germany, Italy, Czechia, France, Netherlands, Japan, Poland, Argentina, Sweden
Nektar Therapeutics

Completed

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Cervical Cancer | Colorectal Cancer | Head and Neck Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Mahana Therapeutics

Completed

Mahana Tinnitus Pilot

Tinnitus

United States
Lykos Therapeutics

Completed

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD (MAPPUSX)

PTSD

United States, Canada, Israel
Tempest Therapeutics

Active, not recruiting

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Colorectal Cancer | Solid Tumor | Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Endometrial Cancer | Urothelial Carcinoma | Gastroesophageal Junction Adenocarcinoma | Solid Tumors With PIK3Ca Mutation

United States
Sangamo Therapeutics

Enrolling by invitation

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Fabry Disease | Fabry Disease, Cardiac Variant

United States, Australia, United Kingdom
Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Tinea Pedis | Tinea Cruris

United States
Sangamo Therapeutics

Enrolling by invitation

Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

End Stage Renal Disease | Kidney Transplant Rejection

Belgium, Netherlands, United Kingdom
Amicus Therapeutics

Active, not recruiting

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Pompe Disease

United States, Netherlands, United Kingdom, Australia, Germany, New Zealand

Clinical Trials Sponsored by Precision Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations